BioCentury
ARTICLE | Company News

Sarepta, BioMarin settle Exondys 51 patent dispute

July 21, 2017 12:58 AM UTC

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) granted Sarepta Therapeutics Inc. (NASDAQ:SRPT) exclusive, worldwide rights to a patent portfolio for exon-skipping products. The deal settles patent litigation between the companies related to Sarepta’s Duchenne muscular dystrophy (DMD) drug Exondys 51 eteplirsen.

Exondys 51 is a phosphorodiamidate morpholino oligomer (PMO) that induces skipping of exon 51 in dystrophin mRNA. FDA granted accelerated approval to the drug last year...